Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Tuesday 9 January 2018, 10:00-12:40

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh – Chair
2. Dr Lindsay Smith – Vice Chair
3. Dr Nabeel Alsindi
4. Professor David Bowen
5. Dr Matthew Bradley
6. Mrs Susan Dutton
7. Mrs Gillian Ells
8. Professor Paula Ghaneh
9. Dr Peter Hall
10. Rebecca Harmston
11. Dr David Meads
12. Mr Malcolm Oswald
13. Professor Oluwafemi Oyebode
14. Dr Paula Parvulescu
15. Dr William Turner

In attendance:
Adrian Bagust
Assessment Group representative, Liverpool Reviews and Implementation Group
Present for notes 1 to 13

Anna Brett
Technical Analyst, National Institute for Health and Clinical Excellence
Present for notes 17 to 19

Peter Clark
CDF Clinical Lead, NHSE
Present for all notes

Nigel Fleeman
Assessment Group representative, Liverpool Reviews and Implementation Group
Present for notes 1 to 13

Helen Knight
Associate Director, National Institute for Health and Care Excellence
Present for all notes
Abitha Senthinathan  Technical Analyst, National Institute for Health and Care Excellence  Present for notes 1 to 16

Jonathan Wadsley  Consultant Clinical Oncologist, Clinical Expert, nominated by AbbVie  Present for notes 1 to 13

Ashley West  Administrator, National Institute for Health and Clinical Excellence  Present for all notes

Stephanie Yates  Project Manager, National Institute for Health and Care Excellence  Present for all notes

Non-public observers:

Ann Greenwood  Senior Editor, National Institute for Health and Care Excellence  Present for all notes

Gavin Kenny  Assistant Project Manager, National Institute for Health and Care Excellence  Present for all notes

Maroulla Whitely  Costings, National Institute for Health and Care Excellence  Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] and cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56].

2. Apologies were received from Dr Aomesh Bhatt, Professor Rachel Elliott and Sumithra Maheswaran.

Any other Business

3. None
Part 1 – Open session

4. The Chair welcomed the invited experts: Adrian Bagust, Dr Peter Clark, Nigel Fleeman and Dr Jonathan Wadsley, to the meeting and they introduced themselves to the Committee.

5. The Chair welcomed company representatives from Bayer and Eisai to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

6.1. Dr Nabeel Alsindi, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Mrs Gillian Ellis, Professor Paula Ghanem, Dr Rebecca Harmston, Professor Gary McVeigh, Dr David Meads, Dr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

6.2. Dr Peter Hall declared a non-personal non-specific financial interest as the University of Edinburgh had received speaker fees on his behalf from Eisai on an unrelated topic.

7.2.1. It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

6.3. Mr William Turner declared a non-specific personal financial interest as his wife held shares in Worldwide Healthcare Trust PLC until mid-June 2017.

7.3.1. It was agreed that this declaration would not prevent Mr William Turner from participating in this section of the meeting.

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

8. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

8.1. Adrian Bagust, Dr Peter Clark and Nigel Fleeman declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be
considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

8.2. Dr Jonathan Wadsley declared a personal non-specific financial interest as he had previously acted as an adviser and attended advisory boards for both Eisai and Bayer, for which he had been paid.

8.2.1. It was agreed that this declaration would not prevent Dr Jonathan Wadsley from participating in this section of the meeting.

8.3. Dr Jonathan Wadsley also declared a non-personal financial interest as he is chief investigator for an Eisai-sponsored clinical trial at Sheffield Teaching Hospital NHS Foundation Trust.

8.3.1. It was agreed that this declaration would not prevent Dr Jonathan Wadsley from participating in this section of the meeting.

9. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059].

14.1. The committee decision was based on consensus.

15. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56]**

Part 2 only

Part 2 – Closed session

16. Discussion on confidential information supplied by the company.
17. The Committee continued to discuss the clinical and cost effectiveness of cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56].

17.1. The committee decision was based on consensus.

18. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) for cabozantinib only in line with their decisions.

**Date, time and venue of the next meeting**

19. Tuesday 6 February 2018, 10:00-12:30, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.